Search
Drotaverine
go.drugbank.com/drugs/DB06751ApprovedWithdrawn[A231619] It is a benzylisoquinoline derivative that is structurally related to [papaverine], although it displays more potent antispasmodic activities than papaverine. … It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689]
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[L51973] When administered alongside glucocorticoid replacement in patients with CAH it allows for the use of lower, physiological doses for glucocorticoid replacement, thereby reducing the risks associated
Chlorphentermine
go.drugbank.com/drugs/DB01556ApprovedIllicitWithdrawnIt has properties similar to those of dextroamphetamine. It has been implicated in lipid storage disorders and pulmonary hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1223)
Amikacin
go.drugbank.com/drugs/DB00479ApprovedInvestigationalVet approved[A39531] Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa.
Diphenoxylate
go.drugbank.com/drugs/DB01081ApprovedIllicitInvestigationalAt high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. … When diphenoxylate is used alone, it is classified as a Schedule II.
Meclofenamic acid
go.drugbank.com/drugs/DB00939ApprovedInvestigationalVet approvedIt also inhibits prostaglandin biosynthesis.
Dimazole
go.drugbank.com/drugs/DB13858ApprovedWithdrawnIt was withdrawn in Franch in 1972 due to neuropsychiatric reactions.
Flunitrazepam
go.drugbank.com/drugs/DB01544ApprovedIllicitSome reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.
Indalpine
go.drugbank.com/drugs/DB08953ApprovedWithdrawnIt was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.
OSI-930
go.drugbank.com/drugs/DB05913InvestigationalOSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2).